Fcγ receptors as regulators of immune responses
The DOI matches its Crossref record; 138 of the 139 references it cites were found in a registry or an index.
Abstract
In addition to their role in binding antigen, antibodies can regulate immune responses through interacting with Fc receptors (FcRs). In recent years, significant progress has been made in understanding the mechanisms that regulate the activity of IgG antibodies in vivo. In this Review, we discuss recent studies addressing the multifaceted roles of FcRs for IgG (FcgammaRs) in the immune system and how this knowledge could be translated into novel therapeutic strategies to treat human autoimmune, infectious or malignant diseases.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“FcγR activation induces macrophage phagocytosis.44”
From Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling (2023) · cites this paper as [44]
Citations
Cites
Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900
Dendritic Cells Induce Peripheral T Cell Unresponsiveness under Steady State Conditions in Vivo
Hawiger, D., Inaba, K., Dorsett, Y., Guo, M., Mahnke, K., Rivera, M., Ravetch, J. V., Steinman, R. M., & Nussenzweig, M. C. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.769 · Cited by 1,848
Self-citationShields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835
Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation
Kaneko, Y., Nimmerjahn, F., & Ravetch, J. V. (2006) · Science · doi:10.1126/science.1129594 · Cited by 1,754 · cited 1×
“Evidence that this sugar residue is involved in immune regulatory processes was obtained by studying the mechanism of the anti-inflammatory activity of IVIG therap”
BackgroundSelf-citationDifferential Antigen Processing by Dendritic Cell Subsets in Vivo
Dudziak, D., Kamphorst, A. O., Heidkamp, G. F., Buchholz, V. R., Trumpfheller, C., Yamazaki, S., Cheong, C., Liu, K., Lee, H.-W., Park, C. G., et al. (2007) · Science · doi:10.1126/science.1136080 · Cited by 1,455
Deisenhofer, J. (1981) · PubMed · Cited by 1,422
Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210665200 · Cited by 1,413
Deisenhofer, J. (1981) · Biochemistry · doi:10.1021/bi00512a001 · Cited by 1,333
The Impact of Glycosylation on the Biological Function and Structure of Human Immunoglobulins
Arnold, J. N., Wormald, M. R., Sim, R. B., Rudd, P. M., & Dwek, R. A. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141702 · Cited by 1,307 · cited 1×
“This sugar side chain consists of a conserved biantennary heptasaccharide core structure containing mannose and N-acetylglucosamine (GlcNac) with varying additions of terminal and branching residues such as fucose, GlcNac, galactose and sialic aci”
BackgroundWeng, W.-K., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,300 · cited 1×
“Several studies of lymphoma patients who had received Rituximab, a B-cell depleting chimeric IgG1 antibody that is specific for CD20, revealed that those patients with activating FcγR alleles that had a higher binding affinity for the Fc fragment of the therapeutic antibody displayed significantly improved clinical re…”
Background
Cited by
Items 201–300 of 1,008
Jung, S. T., Reddy, S. T., Kang, T. H., Borrok, M. J., Sandlie, I., Tucker, P. W., & Georgiou, G. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908590107 · Cited by 160
“S6C), and FcγRIIIa (Fig.”
BackgroundInfluentialType I IFN enhances follicular B cell contribution to the T cell–independent antibody response
Swanson, C. L., Wilson, T. J., Strauch, P., Colonna, M., Pelanda, R., & Torres, R. M. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20092695 · Cited by 166
“…the importance of both arms of the antipathogen humoral response: a rapid IgM response to provide antibody capable of neutralizing and controlling the infection and a robust and highly efficient IgG2c response effective at specialized FcRmediated clear ance (Nimmerjahn and Ravetch, 2005, 2008).”
BackgroundThe immunoglobulin, IgG Fc receptor and complement triangle in autoimmune diseases
Karsten, C. M., & Köhl, J. (2012) · Immunobiology · doi:10.1016/j.imbio.2012.07.015 · Cited by 158
“When an antibody is binding to its Fc R, it acquires a horsehoe-like structure, which seems to be crucial for efficient binding. his conformational change is mediated by sugar moieties attached o asparagine 297 (Asp297) residues within the CH2 domain of the c fragment (Nimmerjahn and Ravetch 2008b).”
BackgroundInfluentialDistinct cell-specific control of autoimmunity and infection by FcγRIIb
Brownlie, R. J., Lawlor, K. E., Niederer, H. A., Cutler, A. J., Xiang, Z., Clatworthy, M. R., Floto, R. A., Greaves, D. R., Lyons, P. A., & Smith, K. G. C. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20072565 · Cited by 162
The role of Fc gamma receptors in the activity of immunomodulatory antibodies for cancer
Stewart, R., Hammond, S. A., Oberst, M., & Wilkinson, R. W. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-014-0029-x · Cited by 157
“Rankings are based on KA x10 M for each interaction reported in published studies [1,5,6].”
BackgroundMethodNanomedicine‐Boosting Tumor Immunogenicity for Enhanced Immunotherapy
Huang, J., Yang, B., Peng, Y., Huang, J., Wong, S. H. D., Bian, L., Zhu, K., Shuai, X., & Han, S. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202011171 · Cited by 157
Clinical Cancer Therapy by NK Cells via Antibody‐Dependent Cell‐Mediated Cytotoxicity
Alderson, K. L., & Sondel, P. M. (2011) · BioMed Research International · doi:10.1155/2011/379123 · Cited by 156
“To date, only one inhibitory FcγR, FcγRIIb, has been identified and is the only receptor to have complete homology between mice and humans [11].”
BackgroundRevisiting the Role of Glycosylation in the Structure of Human IgG Fc
Borrok, M. J., Jung, S. T., Kang, T. H., Monzingo, A. F., & Georgiou, G. (2012) · ACS Chemical Biology · doi:10.1021/cb300130k · Cited by 158
Alpert, M. D., Harvey, J. D., Lauer, W. A., Reeves, R. K., Piatak, M., Carville, A., Mansfield, K. G., Lifson, J. D., Li, W., Desrosiers, R. C., et al. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002890 · Cited by 180
“In addition to virus neutralization, the antiviral functions of antibodies include complement fixation and numerous consequences of Fc receptor crosslinking, such as ADCC [13,24–29].”
BackgroundPeripheral monocytes are functionally altered and invade the CNS in ALS patients
Zondler, L., Müller, K., Khalaji, S., Bliederhäuser, C., Ruf, W. P., Grozdanov, V., Thiemann, M., Fundel-Clemes, K., Freischmidt, A., Holzmann, K., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1548-y · Cited by 154
New roles for Fc receptors in neurodegeneration-the impact on Immunotherapy for Alzheimer's Disease
Fuller, J. P., Stavenhagen, J. B., & Teeling, J. L. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00235 · Cited by 154
“There are four known murine FcγRs: activating (FcγRI, FcγRIII, and FcγRIV) and inhibitory (FcγRIIb) (Nimmerjahn and Ravetch, 2008).”
BackgroundInfluentialNimmerjahn, F., & Ravetch, J. V. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_86 · Cited by 180
Self-citationThe role of Fc–FcγR interactions in IgG-mediated microbial neutralization
Bournazos, S., DiLillo, D. J., & Ravetch, J. V. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20151267 · Cited by 153
“FcR cross-linking triggers antibody-dependent cellular cytotoxicity and/or phagocytosis (ADCC/ADCP), in which IgG bridges target cells or microbes and FcRexpressing effector cells to mediate cytotoxicity or phagocytosis (Nimmerjahn and Ravetch, 2008).”
BackgroundSelf-citationBrezski, R. J., & Jordan, R. E. (2010) · mAbs · doi:10.4161/mabs.2.3.11780 · Cited by 153
Size-Dependent Segregation Controls Macrophage Phagocytosis of Antibody-Opsonized Targets
Bakalar, M. H., Joffe, A. M., Schmid, E. M., Son, S., Podolski, M., & Fletcher, D. A. (2018) · Cell · doi:10.1016/j.cell.2018.05.059 · Cited by 160
Wang, S., Liu, H., Zhang, X., & Qian, F. (2015) · Protein & Cell · doi:10.1007/s13238-015-0164-2 · Cited by 151
“Protein Ag fused to IgG or Fc can specifically target IgG/ Fc-receptors constitutively expressed on APCs to enhance humoral and cellular immunity (Nimmerjahn and Ravetch, 2008; Gosselin et al., 2009) .”
Age‐associated B cells: key mediators of both protective and autoreactive humoral responses
Naradikian, M. S., Hao, Y., & Cancro, M. P. (2016) · Immunological Reviews · doi:10.1111/imr.12380 · Cited by 153
The Role of Fc Receptors on the Effectiveness of Therapeutic Monoclonal Antibodies
Gogesch, P., Dudek, S., van Zandbergen, G., Waibler, Z., & Anzaghe, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168947 · Cited by 172
Natural Killer cells at the frontline in the fight against cancer
Coënon, L., Geindreau, M., Ghiringhelli, F., Villalba, M., & Bruchard, M. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06976-0 · Cited by 187
Structural basis for binding of human IgG1 to its high-affinity human receptor FcγRI
Kiyoshi, M., Caaveiro, J. M. M., Kawai, T., Tashiro, S., Ide, T., Asaoka, Y., Hatayama, K., & Tsumoto, K. (2015) · Nature Communications · doi:10.1038/ncomms7866 · Cited by 151
McEnaney, P. J., Parker, C. G., Zhang, A. X., & Spiegel, D. A. (2012) · ACS Chemical Biology · doi:10.1021/cb300119g · Cited by 150
Functional and clinical consequences of Fc receptor polymorphic and copy number variants
Bournazos, S., Woof, J. M., Hart, S. P., & Dransfield, I. (2009) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2009.03980.x · Cited by 157
Vogelpoel, L. T. C., Baeten, D. L. P., de Jong, E. C., & den Dunnen, J. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00079 · Cited by 146
Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics
Golay, J., Semenzato, G., Rambaldi, A., Foà, R., Gaidano, G., Gamba, E., Pane, F., Pinto, A., Specchia, G., Zaja, F., et al. (2013) · mAbs · doi:10.4161/mabs.26008 · Cited by 148
Heldin, C.-H., Lu, B., Evans, R., & Gutkind, J. S. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a005900 · Cited by 146
Fcγ receptor pathways during active and passive immunization
Bournazos, S., & Ravetch, J. V. (2015) · Immunological Reviews · doi:10.1111/imr.12343 · Cited by 146
Self-citationMonocyte Subsets Responsible for Immunoglobulin G-Dependent Effector Functions In Vivo
Biburger, M., Aschermann, S., Schwab, I., Lux, A., Albert, H., Danzer, H., Woigk, M., Dudziak, D., & Nimmerjahn, F. (2011) · Immunity · doi:10.1016/j.immuni.2011.11.009 · Cited by 149
“…the activity of therapeutic antibodies in models of IgG-dependent target cell depletion (Hazenbos et al., 1996; Ioan-Facsinay et al., 2002; Kaneko et al., 2006; Meyer et al., 1998; Nimmerjahn et al., 2005; Nimmerjahn and Ravetch, 2005, 2008; Takai, 2002; Takai et al., 1994; Uchida et al., 2004).”
BackgroundInfluentialSelf-citationGertner-Dardenne, J., Bonnafous, C., Bezombes, C., Capietto, A.-H., Scaglione, V., Ingoure, S., Cendron, D., Gross, E. T. E., Lepage, J.-F., Quillet‐Mary, A., et al. (2009) · Blood · doi:10.1182/blood-2008-08-172296 · Cited by 160
Dheilly, E., Moine, V., Broyer, L., Salgado-Pires, S., Johnson, Z., Papaioannou, A., Cons, L., Calloud, S., Majocchi, S., Nelson, R., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.11.006 · Cited by 146
The Human FcγRII (CD32) Family of Leukocyte FcR in Health and Disease
Anania, J. C., Chenoweth, A. M., Wines, B. D., & Hogarth, P. M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00464 · Cited by 142
“FcγRIIB Modulation of Immunity FcγRIIB was the first immune “checkpoint” defined (72), with mouse studies showing a pivotal role in controlling autoreactive germinal center B cell activation and survival in mice with dysfunction resulting in loss of tolerance and autoimmunity (73, 74).”
BackgroundTRIM21—From Intracellular Immunity to Therapy
Foss, S., Bottermann, M., Jonsson, A., Sandlie, I., James, L. C., & Andersen, J. T. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02049 · Cited by 149
“Extracellular engagement of classical transmembrane-bound Fc receptors results in intracellular activation or inhibitory signal transduction (51, 52) .”
BackgroundHorton, H. M., Chu, S. Y., Ortiz, E., Pong, E., Čemerski, S., Leung, I., Jacob, N., Zalevsky, J., Desjarlais, J. R., Stohl, W., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003412 · Cited by 152
“For example, autoimmune disease is exacerbated in mice lacking FcgRIIb (4, 5), and its restoration rescues mice in systemic lupus erythematosus (SLE), arthritis, and asthma models (6–8).”
BackgroundPhysical Constraints and Forces Involved in Phagocytosis
Jaumouillé, V., & Waterman, C. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01097 · Cited by 143
“The different isoforms of FcγRs have different affinities for the various IgG isotypes (32).”
BackgroundThe role of sialic acid as a modulator of the anti-inflammatory activity of IgG
Böhm, S., Schwab, I., Lux, A., & Nimmerjahn, F. (2012) · Seminars in Immunopathology · doi:10.1007/s00281-012-0308-x · Cited by 152
Self-citationXu, D., Kim, Y. D., Postelnek, J., Vu, M. D., Hu, D., Liao, C., Bradshaw, M., Hsu, J., Zhang, J., Pashine, A., et al. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.187740 · Cited by 149
“Btk also regulates the signaling of other ITAM-containing receptors or adaptors, e.g., DNAX-activating protein of 12 kDa (DAP12) (Koga et al., 2004).”
BackgroundInfluentialInvolvement of Fc Receptors in Disorders of the Central Nervous System
Okun, E., Mattson, M. P., & Arumugam, T. V. (2010) · NeuroMolecular Medicine · doi:10.1007/s12017-009-8099-5 · Cited by 141
“So far, four different classes of FccRs (FccRI, FccRII, FccRIII, and FccRIV) have been reported (Hulse and Woodfolk 2008; Nimmerjahn and Ravetch 2008).”
BackgroundBoosting therapeutic potency of antibodies by taming Fc domain functions
Kang, T. H., & Jung, S. T. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0345-9 · Cited by 137
Jing, Y., Ni, Z., Wu, J., Higgins, L., Markowski, T. W., Kaufman, D. S., & Walcheck, B. (2015) · PLOS ONE · doi:10.1371/journal.pone.0121788 · Cited by 141
“In contrast, CD16a is a transmembrane protein and also the only FcγR expressed by NK cells [4].”
BackgroundMethodMonocyte and Macrophage Abnormalities in Systemic Lupus Erythematosus
Li, Y., Lee, P. Y., & Reeves, W. H. (2010) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-010-0093-y · Cited by 152
“Fc gamma receptors (FccRs), which are involved in phagocytosis, cytolysis, degranulation, and induction of inflammatory cytokines (Nimmerjahn and Ravetch 2008), are among the surface molecules dysregulated in SLE.”
BackgroundPI3Kβ Plays a Critical Role in Neutrophil Activation by Immune Complexes
Kulkarni, S., Sitaru, C., Jakus, Z., Anderson, K. E., Damoulakis, G., Davidson, K., Hirose, M., Juss, J., Oxley, D., Chessa, T. A. M., et al. (2011) · Science Signaling · doi:10.1126/scisignal.2001617 · Cited by 142
“w and recruitment of the protein tyrosine kinase, Syk (30).”
BackgroundInfluentialEpidermolysis Bullosa Acquisita: The 2019 Update
Koga, H., Prost‐Squarcioni, C., Iwata, H., Jonkman, M. F., Ludwig, R. J., & Bieber, K. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2018.00362 · Cited by 158
Wang, L., Gordon, R. A., Huynh, L., Su, X., Min, K.-H. P., Han, J., Arthur, J. S., Kalliolias, G. D., & Ivashkiv, L. B. (2010) · Immunity · doi:10.1016/j.immuni.2010.03.014 · Cited by 140
“…in vivo, including mediating suppression of IFN-g responses, innate immune responses against Listeria monocytogenes and Leishmania, LPS toxicity, and glomerulonephritis (Gerber and Mosser, 2001; Kanamaru et al., 2008; Nimmerjahn and Ravetch, 2008; Park-Min et al., 2007 and references therein).”
Mechanisms of Fc Receptor and Dectin‐1 Activation for Phagocytosis
Goodridge, H. S., Underhill, D. M., & Touret, N. (2012) · Traffic · doi:10.1111/j.1600-0854.2012.01382.x · Cited by 160
Immune complexes regulate bone metabolism through FcRγ signalling
Negishi-Koga, T., Gober, H.-J., Sumiya, E., Komatsu, N., Okamoto, K., Sawa, S., Suematsu, A., Suda, T., Sato, K., Takai, T., et al. (2015) · Nature Communications · doi:10.1038/ncomms7637 · Cited by 137
To fuse or not to fuse: What is your purpose?
Bell, M. R., Engleka, M. J., Malik, A. A., & Strickler, J. E. (2013) · Protein Science · doi:10.1002/pro.2356 · Cited by 150
B-Cell Depletion In Vitro and In Vivo with an Afucosylated Anti-CD19 Antibody
Herbst, R., Wang, Y., Gallagher, S., Mittereder, N., Kuta, E. G., Damschroder, M. M., Woods, R., Rowe, D. C., Cheng, L., Cook, K., et al. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.168062 · Cited by 141
“It has been demonstrated that the removal of fucose from the carbohydrate modification of the mAb Fc preferentially increases the affinity to Fc RIIIA, resulting in increased ADCC effector function (Shields et al., 2002; Nimmerjahn and Ravetch, 2008).”
BackgroundResultInfluentialFcγ Receptor Heterogeneity in Leukocyte Functional Responses
Rosales, C. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00280 · Cited by 161
“For example, Th1-type cytokines such as IFN-γ and the anaphylatoxin C5a upregulate activating FcγRs expression and downregulate FcγRIIb expression (72, 73), whereas Th2-type cytokines, such as interleukin (IL)-4, IL-10, and transforming growth factor-beta upregulate FcγRIIb expression (41, 74).”
BackgroundInfluentialThe role and function of Fcγ receptors on myeloid cells
Bournazos, S., Wang, T. T., & Ravetch, J. V. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.mchd-0045-2016 · Cited by 138
“Several biochemical and biophysical studies have elucidated the precise signaling pathways that are activated following binding of IgG complexes to activating FcγRs (10, 72).”
BackgroundSelf-citationB cell-regulated immune responses in tumor models and cancer patients
Fremd, C., Schuetz, F., Sohn, C., Beckhove, P., & Domschke, C. (2013) · OncoImmunology · doi:10.4161/onci.25443 · Cited by 138
Role of Fcγ receptors in HER2-targeted breast cancer therapy
Musolino, A., Gradishar, W. J., Rugo, H. S., Nordstrom, J. L., Rock, E. P., Arnaldez, F. I., & Pegram, M. D. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003171 · Cited by 156
Emerging Technologies for Making Glycan-Defined Glycoproteins
Wang, L., & Lomino, J. V. (2011) · ACS Chemical Biology · doi:10.1021/cb200429n · Cited by 144
Gillis, C. M., Gouél‐Cheron, A., Jönsson, F., & Bruhns, P. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00254 · Cited by 157
Fcγ receptors: structure, function and role as genetic risk factors in SLE
Li, X., Ptacek, T., Brown, E. E., & Edberg, J. C. (2009) · Genes and Immunity · doi:10.1038/gene.2009.35 · Cited by 158
Copy number, linkage disequilibrium and disease association in the FCGR locus
Niederer, H. A., Willcocks, L., Rayner, T., Yang, W.-L., Lau, Y.-L., Williams, T., Scott, J., Urban, B., Peshu, N., Dunstan, S., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq216 · Cited by 146
“For a SNP and CNV, phased haplotypes were estimated using an maximum likelihood, in which the 3 × 5 table of genotypes ([0,1,2,3,4] CN × [aa aA AA] SNP genotypes) was iteratively mapped onto a 3 × 2 table of haplotypes ([0,1,2] CN × [a, A] SNP alleles).”
MethodSchmitz, N., Dietmeier, K., Bauer, M., Maudrich, M., Utzinger, S., Muntwiler, S., Saudan, P., & Bachmann, M. F. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090199 · Cited by 136
“It is well established that the FcRIIb (FcIIb receptor), expressed on mouse and human basophils and mast cells (Bischoff, 2007), can down-regulate FcRI signaling by cross-linking of the FcRI–IgE and FcRIIb–IgG-Ag complex (Daëron et al., 1995a; Katz, 2002; Bruhns et al., 2005; Kraft and Kinet, 2007; Nimmerjahn and…”
BackgroundAnalytical FcRn affinity chromatography for functional characterization of monoclonal antibodies
Schlothauer, T., Rueger, P., Stracke, J. O., Hertenberger, H., Fingas, F., Kling, L., Emrich, T., Drabner, G., Seeber, S., Auer, J., et al. (2013) · mAbs · doi:10.4161/mabs.24981 · Cited by 136
Recent Advances in the Generation of Antibody–Nanomaterial Conjugates
Sivaram, A. J., Wardiana, A., Howard, C. B., Mahler, S. M., & Thurecht, K. J. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201700607 · Cited by 134
Cutting Edge: Human FcRL4 and FcRL5 Are Receptors for IgA and IgG
Wilson, T. J., Fuchs, A., & Colonna, M. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102651 · Cited by 137
“Mouse studies have clearly shown the importance of FcgRIIb in B cell regulation and autoimmune disease (1).”
BackgroundAntibody-mediated protection against Ebola virus
Saphire, E. O., Schendel, S. L., Gunn, B. M., Milligan, J. C., & Alter, G. (2018) · Nature Immunology · doi:10.1038/s41590-018-0233-9 · Cited by 139
Qi, X., Li, F., Wu, Y. M., Chen, C., Han, P., Wang, J., & Yang, X. (2019) · Nature Communications · doi:10.1038/s41467-019-10088-1 · Cited by 143
Maternal SARS-CoV-2 infection elicits sexually dimorphic placental immune responses
Bordt, E. A., Shook, L. L., Atyeo, C. G., Pullen, K. M., Guzman, R. M. D., Meinsohn, M.-C., Chauvin, M. Y., Fischinger, S., Yockey, L. J., James, K. E., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abi7428 · Cited by 144
Ji, S., Ma, L., Bai, C., Shi, J., Li, H., Potempa, L. A., Filep, J. G., Zhao, J., & Wu, Y. (2009) · The FASEB Journal · doi:10.1096/fj.08-116962 · Cited by 134
Roghanian, A., Teige, I., Mårtensson, L., Cox, K. L., Kovacek, M., Ljungars, A., Mattsson, J., Sundberg, A., Vaughan, A. T., Shah, V., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.005 · Cited by 133
IgG Glycome in Colorectal Cancer
Vučković, F., Τheodoratou, E., Thaçi, K., Timofeeva, M. N., Vojta, A., Štambuk, J., Pučić‐Baković, M., Rudd, P. M., Đerek, L., Servis, D., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1867 · Cited by 142
DiLillo, D. J., & Ravetch, J. V. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0120 · Cited by 132
Self-citationMultiple Mechanisms of Immune Suppression by B Lymphocytes
Klinker, M. W., & Lundy, S. K. (2012) · Molecular Medicine · doi:10.2119/molmed.2011.00333 · Cited by 132
Impact of Glycosylation on Effector Functions of Therapeutic IgG
Abès, R., & Teillaud, J. (2010) · Pharmaceuticals · doi:10.3390/ph3010146 · Cited by 156
“It was therefore postulated that the interaction of sialic-acid-rich IgG glycoforms of IVIg preparation with this unknown sialic-acid sensor receptor might then lead to a trans-upregulation of FcγRIIB on CSF1-dependent macrophages, thus raising the threshold needed for cell activation and the down-modulation of pro-in…”
BackgroundHu, X., Liou, A. K. F., Leak, R. K., Xu, M., An, C., Suenaga, J., Shi, Y., Gao, Y., Zheng, P., & Chen, J. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2014.06.002 · Cited by 131
Gornik, O., Štambuk, T., & Lauc, G. (2011) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2011.12.004 · Cited by 154
“An elaborate genetic system has evolved which enables IgG to efficiently recognize non-self, but after binding to non-self structures IgG has to initiate a response mechanisms which needs to be different for different types of threats [87].”
BackgroundTay, M. Z., Liu, P., Williams, L. D., McRaven, M. D., Sawant, S. S., Gurley, T. C., Xu, T. T., Dennison, S. M., Liao, H., Chenine, A., et al. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005817 · Cited by 140
“Apart from direct sequestration and destruction of pathogens, engagement of innate immune cells also influences the downstream adaptive immune response by stimulating the secretion of inflammatory mediators [2] .”
BackgroundKapłonek, P., Cizmeci, D., Fischinger, S., Collier, A.-R. Y., Suscovich, T. J., Linde, C., Broge, T. A., Mann, C. J., Amanat, F., Dayal, D., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abm2311 · Cited by 139
“The high-affinity FcR was not tested because of its minimal role in tuning antibody effector function (58).”
Neutrophils orchestrate their own recruitment in murine arthritis through C5aR and FcγR signaling
Sadik, C. D., Kim, N. D., Iwakura, Y., & Luster, A. D. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213797109 · Cited by 146
Ouchida, R., Mori, H., Hase, K., Takatsu, H., Kurosaki, T., Tokuhisa, T., Ohno, H., & Wang, J. O. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1210706109 · Cited by 129
Genetics of Kawasaki Disease: What We Know and Don’t Know
Onouchi, Y. (2012) · Circulation Journal · doi:10.1253/circj.cj-12-0568 · Cited by 151
Bieber, K., Hundt, J. E., Yu, X., Ehlers, M., Petersen, F., Karsten, C. M., Köhl, J., Kridin, K., Kalies, K., Kasprick, A., et al. (2022) · Autoimmunity Reviews · doi:10.1016/j.autrev.2022.103236 · Cited by 151
Genetics of SLE: evidence from mouse models
Morel, L. M. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.63 · Cited by 144
In vivo Cytotoxicity of Type I CD20 Antibodies Critically Depends on Fc Receptor ITAM Signaling
de Haij, S., Jansen, J. H. M., Boross, P., Beurskens, F. J., Bakema, J. E., Bos, D. L., Martens, A., Verbeek, J. S., Parren, P. W. H. I., van de Winkel, J. G. J., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4109 · Cited by 128
“cytotoxicity, and facilitate antigen presentation (5).”
Persistent Alterations in Microglial Enhancers in a Model of Chronic Pain
Denk, F., Crow, M., Didangelos, A., Lopes, D. M., & McMahon, S. B. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.04.063 · Cited by 131
“FcɣRs are the main receptors for immunoglobulins, and their balanced response is crucial for a well-adjusted innate immune response (Nimmerjahn and Ravetch, 2008).”
BackgroundZahavi, D. J., Aldeghaither, D. S., O’Connell, A., & Weiner, L. M. (2018) · Antibody Therapeutics · doi:10.1093/abt/tby002 · Cited by 155
“Myeloid cells capable of acting as ADCC effectors are NK cells, monocytes, macrophages, neutrophils, eosinophils, and dendritic cells [9].”
BackgroundThe expanding roles of ITAM adapters FcRγ and DAP12 in myeloid cells
Hamerman, J. A., Ni, M., Killebrew, J. R., Chu, C., & Lowell, C. A. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00841.x · Cited by 129
“Nimmerjahn F, Ravetch JV. Fcc receptors as regulators of immune responses.”
BackgroundFc Receptors for Immunoglobulins and Their Appearance during Vertebrate Evolution
Akula, S., Mohammadamin, S., & Hellman, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096903 · Cited by 126
“All of the IgG and IgE receptors, except one variant of FccRIII in humans, FccRIIIB, also have a transmembrane region that anchors the receptor in the membrane [18].”
BackgroundMimoto, F., Katada, H., Kadono, S., Igawa, T., Kuramochi, T., Muraoka, M., Wada, Y., Haraya, K., Miyazaki, T., & Hattori, K. (2013) · Protein Engineering Design and Selection · doi:10.1093/protein/gzt022 · Cited by 136
“The inhibitory receptor FcgRIIb is the only IgG Fc receptor expressed on B-cells and plays a critical role in regulating B-cell homeostasis (Heyman, 2003; Nimmerjahn and Ravetch, 2008).”
BackgroundGolay, J., & Introna, M. (2012) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2012.02.011 · Cited by 150
Mysore, V., Cullere, X., Mears, J., Rosetti, F., Okubo, K., Liew, P. X., Zhang, F., Madera-Salcedo, I., Rosenbauer, F., Stone, R. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24591-x · Cited by 125
Chung, S., Quarmby, V., Gao, X., Ying, Y., Lin, L., Reed, C., Fong, C., Lau, W., Qiu, Z. J., Shen, A., et al. (2012) · mAbs · doi:10.4161/mabs.19941 · Cited by 127
Related Mechanisms of Antibody Somatic Hypermutation and Class Switch Recombination
Hwang*, J. K., Alt*, F. W., & Yeap, L.-S. (2015) · Microbiology Spectrum · doi:10.1128/microbiolspec.mdna3-0037-2014 · Cited by 126
The Mechanism of Phagocytosis: Two Stages of Engulfment
Richards, D. M., & Endres, R. G. (2014) · Biophysical Journal · doi:10.1016/j.bpj.2014.07.070 · Cited by 162
“Fcγ receptors are expressed in white blood cells in four different classes, distinguished by their antibody affinity (8).”
BackgroundZhang, T., Yuan, Q., Zhao, J.-H., Zhang, Y., Yuan, L., Lan, Y., Lo, Y.-C., Sun, C., Wu, C., Zhang, J., et al. (2015) · Gut · doi:10.1136/gutjnl-2014-308964 · Cited by 137
Complement in therapy and disease
Melis, J. P. M., Strumane, K., Ruuls, S. R., Beurskens, F. J., Schuurman, J., & Parren, P. W. H. I. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.01.028 · Cited by 125
“Fc glycosylation linked to the asparagine residue at amino acid position 297 is critical for the binding of IgG Fc to C1q and the induction of CDC and mutating this site strongly impacts C1q interaction (Nimmerjahn and Ravetch, 2008; Wright and Morrison, 1997).”
BackgroundNeuroprotection in stroke by complement inhibition and immunoglobulin therapy
Arumugam, T. V., Woodruff, T. M., Lathia, J. D., Selvaraj, P. K., Mattson, M. P., & Taylor, S. M. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2008.07.015 · Cited by 125
“The donor pool size is typically around several thousand individuals, which provides a sufficiently large sample number to ensure homogenic consistency but functional heterogeneity (Nimmerjahn and Ravetch, 2008a).”
BackgroundUo, M., Hisamatsu, T., Miyoshi, J., Kaito, D., Yoneno∥, K., Kitazume, M. T., Mori, M., Sugita, A., Koganei, K., Matsuoka, K., et al. (2012) · Gut · doi:10.1136/gutjnl-2012-303063 · Cited by 153
Immunogenetics of Kawasaki disease
Kumrah, R., Vignesh, P., Rawat, A. K., & Singh, S. (2020) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-020-08783-9 · Cited by 128
“FCGR2A gene via its immune receptor tyrosine–based activation motif (ITAM) results in transduction of activation signals into the cells [133].”
BackgroundZhang, T., Finn, D. F., Barlow, J. W., & Walsh, J. J. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.05.071 · Cited by 123
“…immunoglobulin G1(IgG1), immunoglobulin G2a (IgG2a) and immunoglobulin G2b (IgG2b) antibodies on the high affinity IgE receptor (FcεRI), the FcγRI (human), FcγRIIa (mouse and human) or FcγRIII (mouse) receptor by allergen incites antigen-specific mast cell activation (Nimmerjahn and Ravetch, 2008).”
BackgroundJaumouillé, V., Farkash, Y., Jaqaman, K., Das, R., Lowell, C. A., & Grinstein, S. (2014) · Developmental Cell · doi:10.1016/j.devcel.2014.04.031 · Cited by 119
Chung, A. W., Crispin, M., Pritchard, L., Robinson, H., Gorny, M. K., Yu, X., Bailey-Kellogg, C., Ackerman, M. E., Scanlan, C., Zolla-Pazner, S., et al. (2014) · AIDS · doi:10.1097/qad.0000000000000444 · Cited by 122
The Role of FcRn in Antigen Presentation
Baker, K., Rath, T., Pyzik, M., & Blumberg, R. S. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00408 · Cited by 121
Nita, M., Grzybowski, A. E., Ascaso, F. J., & Huerva, V. (2014) · Mediators of Inflammation · doi:10.1155/2014/930671 · Cited by 136
“Activated/inhibited FccRs activate/inhibit function of effector cells, that is, their capability of phagocytosis, cytokine production, and degranulation [99].”
BackgroundPalma, A., Jarrah, A. S., Tieri, P., Cesareni, G., & Castiglione, F. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.01659 · Cited by 122
“…Negative NF-κB Riley et al., 1999; Hutchins et al., 2013 FcgR Positive ERK Sánchez-Mejorada and Rosales, 1998; Sutterwala et al., 1998; Lucas et al., 2005; Nimmerjahn and Ravetch, 2008; Zhang et al., 2009; Luo et al., 2010; Clatworthy et al., 2014; Foey, 2014; Vogelpoel et al., 2014,…”
BackgroundInfluentialIgA, IgA Receptors, and Their Anti-inflammatory Properties
Mkaddem, S. B., Christou, I., Rossato, E., Berthelot, L., Lehuen, A., & Monteiro, R. C. (2014) · Current topics in microbiology and immunology · doi:10.1007/978-3-319-07911-0_10 · Cited by 143
“The ligation of FcRs by Ig and antigen can trigger numerous cellular effector functions including phagocytosis, antibody-dependent cellular cytotoxicity, and the secretion of cytokines or other inflammatory mediators (Nimmerjahn and Ravetch 2008).”
BackgroundRatelade, J., Asavapanumas, N., Ritchie, A. M., Wemlinger, S., Bennett, J. L., & Verkman, A. S. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1172-z · Cited by 122
Metadata
- Authors
- Nimmerjahn, F., & Ravetch, J. V.
- Affiliations
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Rockefeller University (US)
- Venue
- Nature Reviews Immunology
- Published
- 2008-01
- Volume
- 8
- Issue
- 1
- Pages
- 34-47
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W2075901113
- Cited by
- 2,947
- References
- 139
- Citations by year
- 2026: 186 · 2025: 176 · 2024: 158 · 2023: 174 · 2022: 169 · 2021: 196 · 2020: 158 · 2019: 188 · 2018: 151 · 2017: 161 · 2016: 158 · 2015: 170 · 2014: 165 · 2013: 162 · 2012: 181
- FWCI
- 11.09
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Deutsche Forschungsgemeinschaft
- National Institutes of Health
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Keywords
- Fc gamma receptor, IgG, antibody subclasses, immune regulation, therapeutic antibodies, autoimmune disease, infectious diseases, cancer immunotherapy, antibody effector functions
- MeSH terms
- Animals, Humans, Immunoglobulin G, Immunity, Receptors, Fc
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.